DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration.

Author(s): Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z

Affiliation(s): The Royal Hallamshire Hospital, Sheffield, UK. c.r.chapple@sheffield.ac.uk

Publication date & source: 2010-11, BJU Int., 106(9):1332-8.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

OBJECTIVE: To determine whether the efficacy and safety of a combination of tolterodine extended-release (ER) plus alpha-blocker treatment varies with high or low levels of serum prostate-specific antigen (PSA) in men who have persistent overactive bladder (OAB) symptoms after any alpha-blocker monotherapy. PATIENTS AND METHODS: Men aged >/= 40 years were eligible if they reported >/= 8 micturitions/24 h, including >/= 1 urgency episode/24 h with or without urgency urinary incontinence (UUI), and at least some moderate bladder-related problems at baseline despite receiving treatment with an alpha-blocker for >/= 1 month. Exclusion criteria included a postvoid residual urine volume (PVR) of >/= 200 mL and history of acute urinary retention requiring catheterization. Subjects were randomly assigned to tolterodine-ER 4 mg or placebo for 12 weeks; all subjects continued their alpha-blocker treatment throughout the study. Subjects completed 5-day bladder diaries at baseline and week 12, in which they recorded all micturitions and rated the sensation associated with each micturition using the 5-point Urinary Sensation Scale (USS). For this post hoc analysis, efficacy, safety, and tolerability data were stratified by the study median PSA concentration at baseline (1.41 ng/mL). RESULTS: In the tolterodine-ER +alpha-blocker and placebo +alpha-blocker groups, 160 and 159 men, respectively, had PSA levels of <1.41 ng/mL, and 166 and 160 men, respectively, had PSA levels of >/= 1.41 ng/mL. Men with higher PSA levels were slightly older and had higher PVR at baseline compared with men with lower PSA levels. At week 12, improvements in daytime micturitions, 24-h urgency episodes, and daytime urgency episodes were significantly greater with tolterodine-ER +alpha-blocker vs placebo +alpha-blocker both in men with PSA levels of >/= 1.41 ng/mL and those with PSA levels of < 1.41 ng/mL (P < 0.05). Among men with PSA levels of < 1.41 ng/mL, improvements in 24-h micturitions and frequency-urgency sum (sum of USS ratings for all micturitions) were also significantly greater with tolterodine-ER +alpha-blocker vs placebo +alpha-blocker (P < 0.05). There were no significant treatment differences in change in UUI episodes in either PSA group (although only 19% of subjects reported UUI at baseline), nor in nocturnal micturitions or nocturnal urgency episodes. Among men with PSA levels of >/= 1.41 ng/mL, there was a statistically significant increase in PVR (P = 0.036) and decrease in maximum urinary flow rate (Q(max); P = 0.038) with tolterodine-ER +alpha-blocker vs placebo +alpha-blocker; these changes were not considered clinically meaningful. There were no treatment differences for changes in PVR or Q(max) among men with PSA levels of < 1.41 ng/mL. One subject receiving tolterodine-ER +alpha-blocker (PSA concentration of >/= 1.41 ng/mL) and two subjects receiving placebo +alpha-blocker (one each in the PSA concentration subgroups of >/= 1.41 ng/mL and < 1.41 ng/mL) had acute urinary retention requiring catheterization. CONCLUSION: In a 12-week study, the addition of tolterodine-ER to alpha-blocker therapy improved key OAB symptoms and appeared to be well tolerated compared with placebo +alpha-blocker in men with persistent OAB symptoms, regardless of subjects' prostate size as judged by serum PSA concentration. (c) 2010 DRUG SAFETY RESEARCH UNIT.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017